New amendment aligns Indian regulation with global standards for cell‑based therapies

New Delhi – The Ministry of Health announced that the Drugs Rules now cover regenerative medicines, CAR‑T treatments and gene‑editing products. By bringing these advanced therapies under a single licensing regime, India seeks to match international regulatory norms and ensure robust safety oversight.